Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Cabometyx is the third liver cancer drug approved in the past six months.
Those who exercise build up less liver fat, which is tied to inflammation that may give rise to cancer.
“The future of breast cancer therapy is tied to the idea of individualizing treatment for each patient,” says Sara Tolaney, MD, MPH.
Venclexta alone or in combination with Rituxan improved progression-free survival in patients with chronic lymphocytic leukemia.
Researchers compared direct-acting-antiviral treatment outcomes between those with and without a history of liver cancer.
Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
From immunotherapy to liquid biopsies to new research on side effects—here’s what to expect in 2019.
A look back at some of the major news stories we covered this year.
They are geared to the 10 to 15 percent of people with endometrial cancer who are diagnosed with an advanced stage of the disease.
Long-term remission seen in children with leukemia and adults with lymphoma.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
First-in-human pilot of experimental immunotherapy in Merkel cell carcinoma
Experts say Kadcyla should become a new standard of care for adjuvant therapy.
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease.
Alpelisib showed greater benefit in patients selected with a liquid biopsy test.
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.